INNOVIVA, INC. Proceeds from (Repayments of) Restricted Cash, Financing Activities
INNOVIVA, INC. (INVA) reported Proceeds from (Repayments of) Restricted Cash, Financing Activities of $0 for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-05.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities · last filed 2015-11-05
- INNOVIVA, INC. proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2014-09-30 was $8.63M.
- INNOVIVA, INC. proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2013-09-30 was $0.00.
| Period end | Proceeds from (Repayments of) Restricted Cash, Financing Activities 3 month | Proceeds from (Repayments of) Restricted Cash, Financing Activities 6 month | Proceeds from (Repayments of) Restricted Cash, Financing Activities 9 month |
|---|---|---|---|
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-06 | ||
| 2014-09-30 | $8.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$5.60M 10-Q · filed 2015-11-05 | |
| 2014-06-30 | -$14.23M 10-Q · filed 2015-08-06 | ||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $0.00 10-Q · filed 2014-11-04 | |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |